Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and immunologic, genetic, and environmental (SAIGE) triggers. Currently, no single therapy comprehensively addresses all triggers and the full spectrum of AD manifestations, highlighting an unmet need for therapies that simultaneously target all components of the disease continuum.
An expert panel conducted a structured literature review and developed consensus statements during a meeting in March 2025.
The consensus highlighted the triggers and continuum of four interdependent pathological presentations perpetuating disease progression: inflammation, colonization/dysbiosis/infection, xerosis, and pruritus - termed the "four demons". In a phase 2a clinical trial, topical zabalafin hydrogel was shown to reduce inflammation, skin dysbiosis, Staphylococcus aureus colonization/infection, reduce pruritus, and xerosis with minimal adverse effects in patients with mild to moderate AD.
Recognizing AD as a Continuum emphasizes the necessity for multi-targeted therapeutic strategies. By addressing the interconnected processes of inflammation, infection, pruritus, and xerosis within the AD Continuum, zabalafin offers a promising therapeutic option for sustained disease control.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2025.
All research outputs
#31,212,456
of 34,393,205 outputs
Outputs from Journal of Drugs in Dermatology
#1,556
of 1,781 outputs
Outputs of similar age
#300,557
of 348,848 outputs
Outputs of similar age from Journal of Drugs in Dermatology
#17
of 21 outputs
Altmetric has tracked 34,393,205 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,781 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,848 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
